Tweenvest Stocks

Petros Pharmaceuticals, Inc. (OTCPK: PTPI)

Health Care · Pharmaceuticals · US

$0.00

+57.41% today · -86.3% 1Y

Petros Pharmaceuticals, Inc. (OTCPK: PTPI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $180.08K and employs 3 people.

Over the last twelve months the share price has lost 86.3%, trading between 0.00 and 0.03.

Tweenvest scores Petros Pharmaceuticals, Inc. across four factors: quality 27/100. Its strongest factor is quality.

PTPI price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$180.08K
Revenue (TTM)
P/E
EPS
-0.39
Dividend yield
Beta (5Y)
1.92
52-week high
$0.03
52-week low
$0.00
Avg volume (3M)
Shares outstanding
42.37M
Employees
3
Next earnings

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.

ISIN
US71678J3086
Listed since
Dec 2, 2020
Exchange
Pink Sheets LLC
Currency
USD
CompanyMarket capPriceDay
Eli Lilly and CompanyNYSE: LLY$1.11T$1,233.66-1.06%
Johnson & JohnsonNYSE: JNJ$658.24B$273.14+0.04%
Merck & Co., Inc.NYSE: MRK$371.70B$156.45+3.84%
Roche Holding AGSWX: ROP$368.80BCHF373.80+0.92%
Novartis AGSWX: NOVN$300.52BCHF126.76-0.52%
AstraZeneca PLCLSE: AZN$256.25B£124.76+3.02%
Novo Nordisk A/SCPSE: NOVO B$206.64BDkr299.25-0.53%
Pfizer Inc.NYSE: PFE$162.84B$28.57+2.15%

Browse every Pharmaceuticals company →

Figures last refreshed Aug 18, 2026.